"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.

Moderna's been anything but a high-flying growth stock in this investor's portfolio. So is it high time he gave up on this one? The post Moderna’s meant to be a red-hot growth stock. What on earth’s ...

Last year, Moderna and the National Institutes of Health in the US started clinical trials of multiple mRNA-based HIV vaccine candidates, including some intended for use in combination ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

Moderna's mRNA vaccine platform has already delivered the ... respiratory syncytial virus (RSV), HIV, malaria and tuberculosis. Sun Pharma's Taro unit has made a bid to acquire Canadian biotech ...

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally, posing a particularly significant threat to people with HIV ... to Moderna to develop mRNA vaccines against ...

Following his speech, Trump signed a slew of executive orders—declaring a national emergency at the southern border and an end to birthright citizenship, as well as ending use of the CBP1 app, among ...

Warning Bells Ring as Leading Epidemiologist Exposes Gates' 'Bioterrorism' Agenda** In a shocking disclosure, top epidemiologist Nicolas Hulscher of the McCullough Foundation ha ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...

A unique reaction in which antibodies bind to other antibodies may help scientists at Scripps Research better understand how to design a vaccine ...